Lunai Bioworks financials
$1.77−4.84%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q3 '26 Mar 31 | Q2 '26 Dec 31 |
|---|---|---|
| Revenue | $20.9K | $0.00 |
| Gross profit | $20.9K | $0.00 |
| Gross margin | 100.0% | — |
| Operating income | -$1.4M | -$1.8M |
| Net income | -$2.6M | -$1.8M |
| Net margin | −12278.6% | — |
| Diluted EPS | $-0.80 | $-0.64 |
| EBITDA | -$1.4M | -$1.8M |
| Operating cash flow | -$1.0M | -$1.1M |
| Free cash flow | -$1.0M | -$1.1M |
| Diluted shares | 3.1M | 2.9M |
Balance sheet
| Period end | Mar 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $3.2M | $491.6K |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $120.0K | $1.4M |
| Total assets | $9.9M | $6.7M |
| Total liabilities | $19.4M | $20.2M |
| Shareholders' equity | -$9.6M | -$13.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology